Novo Nordisk's CagriSema delivers 21% weight loss at 68 weeks in obesity trial

PUBT · 1d ago
Novo Nordisk's CagriSema delivers 21% weight loss at 68 weeks in obesity trial
  • Novo Nordisk reported CagriSema trial results on November 4, 2026, showing greater weight loss than tirzepatide in adults with diabetes and obesity.
  • The REIMAGINE 5 trial also showed CagriSema was non-inferior to tirzepatide in reducing blood sugar.
  • Separately reported REDEFINE 9 results showed weight loss with CagriSema in obesity.
  • The phase 3 AMAZE 9 trial of oral zenagamtide in obesity began in September.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040130OMX_____CNEWS_EN_GNW1001301674_en) on November 04, 2026, and is solely responsible for the information contained therein.